Pharma-focused facility IMCA-CAT is a synchrotron-based structural biology facility tailored for industrial macromolecular crystallography and pharmaceutical drug discovery, indicating a primary sales angle around confidential, high-throughput structural data services for pharma clients.

Ultra high-throughput The operation is optimized for ultra high-throughput data acquisition with state-of-the-art technology to deliver high-quality X-ray diffraction data, suggesting opportunities to upsell rapid turnaround, large-scale screening, and large compound libraries.

Confidential access Confidential and proprietary crystallography experiments are supported, which is attractive for pharmaceutical companies requiring secure data handling and NDAs, providing a path for enterprise contracts and long-term access arrangements.

Strategic partnerships Located at the Advanced Photon Source in collaboration with Hauptman-Woodward Medical Research Institute, highlighting a credibility and capability angle that can be leveraged to co-sell with industry partners and expansion into allied research services.

Growth potential Revenue range indicates a small, focused service provider with potential for scale via increased client diversification, expanded service lines in structural biology, and cross-selling to related biopharma CROs and biotech firms.